Grant of Options and Extension of Warrant Term
Hemogenyx Pharmaceuticals plc announced the grant of 1,200,000 ordinary share options to its Non-Executive and Executive Directors, and an additional 60,000 options to employees, all with an exercise price of £8 and expiring on 29 May 2031. Following these grants, a total of 1,410,479 shares are under option, representing 20.7% of the issued share capital. Additionally, the company has extended the term of 69,048 investor warrants from their original grant date of 8 March 2025 to 7 September 2026, aligning them with other existing warrants without changing the exercise price.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, announces the grant of share options and a variation to the exercise period for certain investor warrants.
Grant of Share Options
The Board of Directors has agreed to grant options over a total of 1,200,000 ordinary shares of 1p each in the capital of the Company ("Board Share Options") to the Company's Non-Executive Directors Peter Redmond, Alexis Sandler, Sir Marc Feldmann (Chairman) and Executive Director Vladislav Sandler (CEO).
The details of the Board Share Options granted are set out below:
| Name | Position | Number of Share Options Granted | Exercise Price (pounds) | Expiry Date |
|---|---|---|---|---|
| Peter Redmond | Non-executive Director | 300,000 | 8.0 | 29 May 2031 |
| Sir Marc Feldmann | Non-executive Chairman | 300,000 | 8.0 | 29 May 2031 |
| Vladislav Sandler | CEO | 300,000 | 8.0 | 29 May 2031 |
| Alexis Sandler | Non-executive Director | 300,000 | 8.0 | 29 May 2031 |
| Koen Van Besien | Medical Director | 60,000 | 8.0 | 29 May 2031 |
Further, options have been granted to employees over a total of 60,000 ordinary shares of 1p each in the capital of the Company ("Employee Share Options"). The Employee Share Options will have an exercise price of £8 and expire on 29 May 2031.
The Board and Employee Share Options will vest immediately.
Following the grant of the Board and Employee Share Options there are, in aggregate, 1,410,479 ordinary shares of 1p each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company, representing 20.7% of the issued ordinary share capital of the Company.
Extension to warrant exercise period
The Company has extended the term of 69,048 warrants granted to a group of investors to 7 September 2026 (the "Warrants"). The Warrants were originally granted to the investors on 8 March 2025 with a term of fifteen months.
The Board has concluded that the term of the Warrants should be extended to be aligned with the terms of other existing warrants. All other terms of the Warrants remain unchanged including the exercise price.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.